People | April 22, 2026
ECI taps industry veteran Khalid Raja to drive strategic growth
Move comes amid rising regulatory pressures
Move comes amid rising regulatory pressures
The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform
The move aims to accelerate the development, commercialization, and global rollout of advanced AI-powered mammography tools
The aim is to bolster healthcare delivery in a region increasingly burdened by chronic disease
The company reported net revenue of SEK 13.5 million for the full year 2025
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Minister highlights RDI fund, private participation in space and nuclear sectors, and calls for faster reforms to improve ease of research in India
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
